MorphoSys formed a 3-year strategic alliance with Novartis to discover and develop antibody-based therapeutics for a variety of diseases. The collaboration will utilize MorphoSys’ HuCAL GOLD® technology to generate and optimize antibodies against targets identified by Novartis.